[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-grade-sarcoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-grade-sarcoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100641916","phase-2-fluorescence-guided-surgical-resection-for-reducing-unexpected-positive-margins-in-patients-with-sarcoma-sarcosight-trial-100641916",false,"NCT07650656","Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial","SarcoSIGHT: A Randomized-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care","Inclusion Criteria:\n\n* Documented written informed consent of the participant\n* Histologically confirmed diagnosis of intermediate to high grade sarcoma\n* All ages\n* Amenable to surgical resection as a part of curative intent for the patient\n* Willingness to:\n\n  * Respond to surveys during the trial\n  * Permit medical record\u002F clinical laboratory result review\n\nExclusion Criteria:\n\n* Due for surgery with palliative intent\n* Recurrent tumors\n* Intracranial, retroperitoneal, and visceral anatomical locations\n* A woman of childbearing potential who is currently pregnant (as confirmed by urine pregnancy test)\n* A woman who are currently breastfeeding\n* Known allergies to ICG, iodine, iodine dyes or shellfish\n* Unable to provide written and informed consent\n* Patients with hyper-thyroidism or autonomic thyroid adenomas\n* Premature infants\u002Fneonates with exchange transfusion indication due to hyperbilirubinemia","ALL",{"count":18,"type":19},22,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This phase II trial compares standard of care surgical resection to fluorescence-guided surgical resection using indocyanine green and fluorescence imaging for reducing unexpected positive margin rates in patients with sarcoma. Surgical margins are one of the criteria used in assessing the effectiveness of a given surgical procedure. They are the edges or border of the tissue removed in cancer surgery. A negative margin means that the resected tumor is surrounded by normal tissue, which implies there is no disease left in the patient. By contrast, a positive margin means that sarcoma cells are visible at the edge of the tumor. Positive margins may be classified as planned when they are expected pre-operatively due to the preservation of a critical structure, or unexpected when the pathologist reports the presence of tumor at the margin despite the surgeon having intended to remove it in its entirety. Fluorescence-guided surgery is an established surgical method that involves the administration of fluorescent dye (in this case, indocyanine green) into the tumor, which can then be visualized with a special camera during surgery to help surgeons identify tumor versus healthy tissue. Fluorescence-guided surgery may reduce the rate of unexpected positive margins in patients undergoing surgery for sarcoma.",[25,26],"High Grade Sarcoma","Sarcoma","RECRUITING","2026-06-17",{"date":30,"type":31},"2026-06-22","ACTUAL",{"date":33,"type":19},"2027-05-15",{"date":35,"type":19},"2028-05-11",{"name":37,"class":38},"City of Hope Medical Center","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":39},"100462409","phase-2-habitat-escalated-adaptive-therapy-heat-with-neoadjuvant-radiation-for-soft-tissue-sarcoma-100462409","NCT05301283","Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma","Phase 2 Clinical Trial of Radiomic Habitat-Directed Radiation Dose Escalation for High-Grade Soft Tissue Sarcoma","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* For women of childbearing potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 52 weeks after the end of radiation.\n* For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner 52 weeks after radiation.\n* Agreement to adhere to Lifestyle Considerations (as outlined in protocol) throughout study duration.\n* Pathologically (histologically or cytologically) proven diagnosis of high-grade (grade 2 or 3) Soft Tissue Sarcoma (STS) of the deep trunk and\u002For extremity. Clinical evidence should be documented, and may consist of pathology or imaging, and should be sufficient to estimate the size of the primary (for T stage)\n* Primary site deemed resectable prior to the start of trial\n* American Joint Committee on Cancer (AJCC) 8th edition staging T1-4 N0 M0, no evidence of distant metastases\n* Patients must have clinically or radiographically evident measurable disease at the primary site.\n* Pre-Radiation Therapy (RT) MRI within 4 weeks of the start of RT.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 3.\n* Deemed a surgical candidate\n* Participant agrees to blood and plasma preservation for future analysis.\n\nExclusion Criteria:\n\n* Contraindications to an MRI\n* Positive urine pregnancy test\n* Gross total excision of primary STS, including an unplanned excision\n* Superficial sarcoma located primarily in the subcutaneous or cutaneous tissue\n* Prior radiation to the region of the study cancer that would result in overlap of radiation therapy fields.\n* Participants with a medical condition or social situation that, at the discretion of the principal investigator, would preclude them from completion of the trial.","18 Years",{"count":49,"type":19},43,[22],"The purpose of the study is to utilize radiomic images to precisely locate areas of tumor that can be treated with dose escalation radiation therapy.",[25],"2025-12-03",{"date":55,"type":31},"2025-12-04",{"date":57,"type":31},"2022-05-18",{"date":59,"type":19},"2026-08",{"name":61,"class":38},"H. Lee Moffitt Cancer Center and Research Institute",{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":70,"targetDuration":72,"studyType":73,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100478829","registry-for-children-adolescents-and-adults-with-osteosarcoma-and-biologically-related-bone-sarcomas-100478829","NCT05515068","Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas","Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas (COSS-Registry)","COSS-Registry","Inclusion Criteria:\n\n* high-grade osteosarcoma (conventional and non-conventional)\n* parosteal, periosteal or extraosseous osteosarcoma\n* low grade central osteosarcoma\n* (osseous) Undifferentiated pleomorphic sarcoma (UPS)\n* (osseous) leiomyosarcoma\n* (osseous) dedifferentiated chondrosarcoma\n* (osseous) mesenchymal chondrosarcoma\n* (osseous) fibrosarcoma\n* (osseous) angiosarcoma\n* informed consent\n\nExclusion Criteria:\n\n* no informed consent",{"count":71,"type":19},1000,"20 Years","OBSERVATIONAL","The Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas (COSS-Registry) is a non-interventional, multicentric, international, clinical and epidemiologic patient registry. The COSS-Registry collects key data on osteosarcomas or biologically related bone sarcomas. With that data collection we want to gain new scientific insights and results about this tumor disease, prognosis, surveillance and long-term effects.\n\nBesides the data collection we would also like to foster the collection of biomaterial (tumor specimen and blood samples) for scientific research.\n\nThe stored material will be used to perform cell and molecular biological analyses to identify the causes of osteosarcoma, the prognosis and possible new treatment options.\n\nAs a starting point the donated biomaterial of registered patients will be analyzed firstly for the presence of a tumor predisposition by germline mutations.\n\nIn case of detected genetic variations that are related to the tumor disease and which may affect the patient's health and follow-up care (because of the potentially increased risk of developing other malignant tumors), affected patients will be informed and referred to genetic counseling.\n\nRegistry patients will be asked at the time of diagnosis if they wish to be informed about germline variants detected as part of the study procedures.",[76,77,78,25,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100],"Osteosarcoma","Bone Tumor","Bone Sarcoma","Osteoblastic Osteosarcoma","Chondroblastic Osteosarcoma","Fibroblastic Osteosarcoma","Conventional Osteosarcoma","Conventional Central Osteosarcoma of Bone","Low Grade Central Osteosarcoma","Osseous Sarcoma","Osseous Tumor","Small Cell Osteosarcoma","Telangiectatic Osteosarcoma","Undifferentiated Pleomorphic Sarcoma","Parosteal Osteosarcoma","Periosteal Osteosarcoma","Extraskeletal Osteosarcoma","Recurrent Osteosarcoma","High Grade Surface Osteosarcoma","Osseous Angiosarcoma","Osseous Fibrosarcoma","Osseous Leiomyosarcoma","Osseous Dedifferentiated Chondrosarcoma","Osseous Mesenchymal Chondrosarcoma","Clear Cell Osteosarcoma","NOT_YET_RECRUITING","2022-08-24",{"date":104,"type":31},"2022-08-25",{"date":106,"type":19},"2022-09",{"date":108,"type":19},"2032-03",{"name":110,"class":38},"Klinikum Stuttgart"]